A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors

Trial Profile

A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs RO 7198457 (Primary) ; Atezolizumab
  • Indications Tumours
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 11 Dec 2017 Planned initiation date changed from 7 Dec 2017 to 30 Dec 2017.
    • 23 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 26 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top